Associated Papers
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of KRAS Mutations.
Motta L et al.
Cancers, 2025
Aspyre Lung enables robust variant calling in samples that fail next generation sequencing quality control.
Gray ER et al.
Translational Oncology, 2025
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer.
Sposito M et al.
Scientific Reports, 2025
DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer.
Tan S et al.
Cancer, 2025
The Role of miR-29a and miR-143 on the Anti-apoptotic MCL-1/cIAP-2 Genes Expression in EGFR Mutated Non-small Cell Lung Carcinoma Patients.
Abrehdari-Tafreshi Z et al.
Biochemical Genetics, 2024
Inflammatory Giant Cell Carcinoma of the Lung: Clinicopathologic, Immunohistochemical, and Next-generation Sequencing Study of 14 Cases.
Suster DI et al.
The American Journal of Surgical Pathology, 2024
Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.
Garrido J et al.
Bmc Cancer, 2024
Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition.
Bando H et al.
Cancer Science, 2024
Association of mutation profiles with metastasis in patients with non-small cell lung cancer.
Li Y et al.
Frontiers in Oncology, 2024
RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.
Addeo A et al.
Pharmacology & Therapeutics, 2023
Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer-Data from Daily Practice.
Knetki-Wróblewska M et al.
Current Oncology (toronto, Ont.), 2022
Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis.
Tabata J et al.
Cancer Research, 2022
Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer.
Church AJ et al.
Nature Medicine, 2022
Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study.
Paliogiannis P et al.
Bmc Pulmonary Medicine, 2022
Papillary renal neoplasm with reverse polarity: A clinicopathological and molecular genetic characterization of 16 cases with expanding the morphologic spectrum and further support for a novel entity.
Shen M et al.
Frontiers in Oncology, 2022
[Advances in Lung Cancer Treatment].
Schulz C
Deutsche Medizinische Wochenschrift (1946), 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV et al.
Journal for Immunotherapy of Cancer, 2021
Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: a single institution experience.
Burns EA et al.
Journal of Thoracic Disease, 2021
Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.
Yang J et al.
Frontiers in Oncology, 2021
Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico.
Zheng R et al.
Cancers, 2020
Long-read sequencing for non-small-cell lung cancer genomes.
Sakamoto Y et al.
Genome Research, 2020
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
Egan C et al.
Haematologica, 2020
The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer.
Zhang Y et al.
Journal for Immunotherapy of Cancer, 2019
Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A et al.
Diagnostic Pathology, 2019
Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics.
Shaukat I et al.
Human Pathology, 2019
Targeted Sequencing Analysis of Pulmonary Adenocarcinoma with Multiple Synchronous Ground-Glass/Lepidic Nodules.
Park E et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2018
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL et al.
Journal of Gastrointestinal Oncology, 2018
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.
Kato S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
Wen YS et al.
Medicine, 2014
A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma.
Ross JS et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
Morris EJ et al.
Cancer Discovery, 2013
Characteristics of lung cancers harboring NRAS mutations.
Ohashi K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Keratinocytic epidermal nevi are associated with mosaic RAS mutations.
Hafner C et al.
Journal of Medical Genetics, 2012
KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Tie J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer.
Simi L et al.
American Journal of Clinical Pathology, 2008
Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status.
Hsu J et al.
Clinical Pathology (thousand Oaks, Ventura County, Calif.), 0